Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Uterine Cervical Neoplasms | 24 | 2023 | 2018 | 4.720 |
Why?
|
Carcinoma, Endometrioid | 10 | 2022 | 271 | 3.550 |
Why?
|
Uterine Neoplasms | 15 | 2023 | 1513 | 3.260 |
Why?
|
Endometrial Neoplasms | 20 | 2023 | 1350 | 3.230 |
Why?
|
Ovarian Neoplasms | 21 | 2023 | 4839 | 3.030 |
Why?
|
Papillomavirus Infections | 11 | 2023 | 1587 | 2.660 |
Why?
|
Adenocarcinoma | 18 | 2023 | 6363 | 2.600 |
Why?
|
Leiomyosarcoma | 7 | 2023 | 477 | 2.360 |
Why?
|
Carcinoma in Situ | 6 | 2022 | 805 | 2.340 |
Why?
|
Vulvar Neoplasms | 4 | 2023 | 272 | 2.180 |
Why?
|
Adenocarcinoma, Mucinous | 8 | 2023 | 507 | 2.100 |
Why?
|
Endometrium | 6 | 2023 | 423 | 1.880 |
Why?
|
Smooth Muscle Tumor | 4 | 2023 | 67 | 1.830 |
Why?
|
Placenta | 5 | 2024 | 1699 | 1.600 |
Why?
|
Endometrial Hyperplasia | 2 | 2023 | 97 | 1.590 |
Why?
|
Precancerous Conditions | 3 | 2023 | 975 | 1.530 |
Why?
|
Ovarian Cysts | 2 | 2022 | 115 | 1.520 |
Why?
|
Sex Cord-Gonadal Stromal Tumors | 2 | 2022 | 105 | 1.460 |
Why?
|
Pathology, Clinical | 4 | 2022 | 368 | 1.390 |
Why?
|
Carcinoma | 9 | 2023 | 2375 | 1.280 |
Why?
|
Placenta Accreta | 2 | 2024 | 225 | 1.160 |
Why?
|
Menorrhagia | 2 | 2016 | 63 | 1.090 |
Why?
|
Matrix Attachment Region Binding Proteins | 2 | 2016 | 44 | 1.090 |
Why?
|
Endometriosis | 4 | 2023 | 838 | 1.080 |
Why?
|
Hysterectomy | 9 | 2024 | 927 | 1.060 |
Why?
|
Tumor Suppressor Protein p53 | 7 | 2023 | 2944 | 1.040 |
Why?
|
Immunohistochemistry | 23 | 2023 | 11360 | 0.990 |
Why?
|
Adenosarcoma | 3 | 2021 | 34 | 0.970 |
Why?
|
Antigens, Differentiation | 3 | 2018 | 927 | 0.930 |
Why?
|
Placenta Previa | 1 | 2024 | 117 | 0.840 |
Why?
|
Female | 112 | 2024 | 380020 | 0.830 |
Why?
|
Carcinoma, Intraductal, Noninfiltrating | 4 | 2019 | 948 | 0.820 |
Why?
|
beta Catenin | 3 | 2022 | 1060 | 0.800 |
Why?
|
Placenta Diseases | 1 | 2023 | 199 | 0.780 |
Why?
|
Vulvar Diseases | 1 | 2021 | 61 | 0.780 |
Why?
|
Endodermal Sinus Tumor | 1 | 2021 | 47 | 0.760 |
Why?
|
Myofibroma | 1 | 2021 | 50 | 0.750 |
Why?
|
Carcinoma, Verrucous | 1 | 2020 | 23 | 0.740 |
Why?
|
Sarcoma, Endometrial Stromal | 2 | 2019 | 91 | 0.730 |
Why?
|
Trophoblasts | 2 | 2023 | 215 | 0.710 |
Why?
|
Leiomyoma | 2 | 2023 | 730 | 0.710 |
Why?
|
Adenomatous Polyposis Coli | 1 | 2021 | 223 | 0.700 |
Why?
|
Authorship | 1 | 2022 | 271 | 0.690 |
Why?
|
DNA Polymerase II | 1 | 2019 | 107 | 0.680 |
Why?
|
Myometrium | 2 | 2016 | 181 | 0.660 |
Why?
|
DNA Mismatch Repair | 3 | 2022 | 426 | 0.640 |
Why?
|
Hypertension, Pregnancy-Induced | 1 | 2023 | 489 | 0.600 |
Why?
|
Papillomaviridae | 7 | 2022 | 1119 | 0.600 |
Why?
|
Endometrial Stromal Tumors | 2 | 2018 | 44 | 0.600 |
Why?
|
Neoplasm Staging | 20 | 2023 | 11036 | 0.600 |
Why?
|
Chorionic Villi | 1 | 2016 | 51 | 0.580 |
Why?
|
Biopsy | 12 | 2021 | 6750 | 0.570 |
Why?
|
Humans | 116 | 2024 | 743811 | 0.570 |
Why?
|
Endometrial Ablation Techniques | 1 | 2016 | 11 | 0.570 |
Why?
|
Receptors, Estrogen | 3 | 2023 | 2190 | 0.560 |
Why?
|
Neoplasms, Glandular and Epithelial | 2 | 2018 | 484 | 0.560 |
Why?
|
Receptors, Progesterone | 2 | 2023 | 1098 | 0.550 |
Why?
|
Ovary | 4 | 2023 | 980 | 0.550 |
Why?
|
Forkhead Transcription Factors | 1 | 2023 | 1613 | 0.550 |
Why?
|
Breast | 4 | 2020 | 1970 | 0.540 |
Why?
|
Carcinoma, Ductal, Breast | 4 | 2019 | 1100 | 0.530 |
Why?
|
Neoplasm Invasiveness | 8 | 2023 | 3617 | 0.510 |
Why?
|
Clinical Laboratory Techniques | 1 | 2020 | 738 | 0.510 |
Why?
|
Carcinoma, Lobular | 2 | 2019 | 484 | 0.510 |
Why?
|
Dysmenorrhea | 1 | 2016 | 86 | 0.510 |
Why?
|
Uterus | 4 | 2024 | 711 | 0.510 |
Why?
|
Soft Tissue Neoplasms | 2 | 2022 | 1363 | 0.490 |
Why?
|
Neoplasms, Muscle Tissue | 1 | 2015 | 83 | 0.480 |
Why?
|
Diagnosis, Differential | 11 | 2021 | 12954 | 0.480 |
Why?
|
Mutation, Missense | 1 | 2023 | 2566 | 0.480 |
Why?
|
Appendiceal Neoplasms | 1 | 2016 | 146 | 0.480 |
Why?
|
Vulva | 3 | 2023 | 87 | 0.470 |
Why?
|
Observer Variation | 6 | 2021 | 2592 | 0.470 |
Why?
|
Pre-Eclampsia | 1 | 2023 | 1200 | 0.470 |
Why?
|
Prognosis | 18 | 2023 | 29052 | 0.460 |
Why?
|
Adult | 42 | 2023 | 213889 | 0.450 |
Why?
|
Biological Products | 1 | 2022 | 859 | 0.440 |
Why?
|
Specimen Handling | 3 | 2024 | 694 | 0.430 |
Why?
|
Middle Aged | 46 | 2022 | 213241 | 0.430 |
Why?
|
Disease-Free Survival | 7 | 2021 | 6895 | 0.430 |
Why?
|
Biopsy, Needle | 2 | 2015 | 1639 | 0.430 |
Why?
|
Cervix Uteri | 6 | 2022 | 590 | 0.420 |
Why?
|
Mutation | 8 | 2023 | 29777 | 0.410 |
Why?
|
Breast Neoplasms | 10 | 2020 | 20827 | 0.410 |
Why?
|
Carcinoma, Squamous Cell | 3 | 2022 | 4033 | 0.400 |
Why?
|
DNA Mutational Analysis | 4 | 2022 | 4183 | 0.390 |
Why?
|
Aged | 34 | 2021 | 163178 | 0.380 |
Why?
|
Hemangioma | 1 | 2016 | 738 | 0.380 |
Why?
|
Predictive Value of Tests | 10 | 2021 | 15067 | 0.370 |
Why?
|
Pregnancy Complications, Neoplastic | 1 | 2013 | 255 | 0.370 |
Why?
|
Evidence-Based Medicine | 2 | 2021 | 3608 | 0.370 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2022 | 2027 | 0.370 |
Why?
|
Pregnancy | 9 | 2024 | 29140 | 0.360 |
Why?
|
Decision Support Techniques | 1 | 2019 | 1956 | 0.340 |
Why?
|
Practice Guidelines as Topic | 3 | 2021 | 7270 | 0.340 |
Why?
|
Colonic Neoplasms | 1 | 2021 | 2542 | 0.340 |
Why?
|
Aged, 80 and over | 16 | 2021 | 57744 | 0.330 |
Why?
|
Class I Phosphatidylinositol 3-Kinases | 2 | 2023 | 890 | 0.320 |
Why?
|
Adenocarcinoma, Clear Cell | 2 | 2022 | 221 | 0.320 |
Why?
|
Progesterone | 1 | 2013 | 773 | 0.320 |
Why?
|
Lymph Node Excision | 5 | 2023 | 1262 | 0.320 |
Why?
|
Awards and Prizes | 2 | 2023 | 375 | 0.320 |
Why?
|
Gastrointestinal Neoplasms | 1 | 2016 | 991 | 0.310 |
Why?
|
Stromal Cells | 1 | 2013 | 1356 | 0.310 |
Why?
|
Neoplasm Recurrence, Local | 10 | 2022 | 9239 | 0.290 |
Why?
|
Candidiasis | 1 | 2010 | 366 | 0.290 |
Why?
|
Necrosis | 3 | 2022 | 1642 | 0.290 |
Why?
|
Transcription Factors | 3 | 2023 | 12209 | 0.290 |
Why?
|
Candida albicans | 1 | 2010 | 394 | 0.280 |
Why?
|
Intraoperative Care | 2 | 2021 | 767 | 0.280 |
Why?
|
Pelvic Neoplasms | 2 | 2022 | 254 | 0.280 |
Why?
|
Pancreatic Cyst | 1 | 2010 | 369 | 0.280 |
Why?
|
MutS Homolog 2 Protein | 2 | 2019 | 200 | 0.270 |
Why?
|
Cell Differentiation | 2 | 2013 | 11478 | 0.270 |
Why?
|
Enterocolitis, Necrotizing | 1 | 2010 | 341 | 0.270 |
Why?
|
Cystadenocarcinoma, Serous | 2 | 2021 | 450 | 0.260 |
Why?
|
Retrospective Studies | 26 | 2024 | 77410 | 0.240 |
Why?
|
In Situ Hybridization, Fluorescence | 3 | 2022 | 2649 | 0.240 |
Why?
|
Frozen Sections | 2 | 2021 | 155 | 0.230 |
Why?
|
World Health Organization | 2 | 2020 | 1317 | 0.230 |
Why?
|
Brachytherapy | 3 | 2021 | 1247 | 0.230 |
Why?
|
Algorithms | 3 | 2019 | 13869 | 0.220 |
Why?
|
Proteomics | 1 | 2016 | 3639 | 0.220 |
Why?
|
Databases, Protein | 2 | 2016 | 383 | 0.220 |
Why?
|
Myxosarcoma | 1 | 2022 | 15 | 0.210 |
Why?
|
Canada | 4 | 2022 | 2064 | 0.210 |
Why?
|
Leiomyomatosis | 1 | 2022 | 70 | 0.210 |
Why?
|
Infarction | 1 | 2023 | 244 | 0.210 |
Why?
|
Gynecology | 3 | 2024 | 512 | 0.200 |
Why?
|
Consensus | 2 | 2022 | 2954 | 0.200 |
Why?
|
Pelvic Exenteration | 1 | 2021 | 22 | 0.200 |
Why?
|
Yolk Sac | 1 | 2021 | 75 | 0.200 |
Why?
|
Computational Biology | 1 | 2013 | 3515 | 0.190 |
Why?
|
Carcinosarcoma | 1 | 2021 | 108 | 0.180 |
Why?
|
Receptor, erbB-2 | 2 | 2021 | 2418 | 0.180 |
Why?
|
Diagnostic Imaging | 1 | 2014 | 3503 | 0.180 |
Why?
|
Uterine Rupture | 1 | 2020 | 72 | 0.180 |
Why?
|
Mucin-6 | 1 | 2019 | 15 | 0.180 |
Why?
|
Fibrosarcoma | 1 | 2022 | 345 | 0.180 |
Why?
|
Sentinel Lymph Node Biopsy | 2 | 2021 | 710 | 0.180 |
Why?
|
Sensitivity and Specificity | 4 | 2021 | 14714 | 0.180 |
Why?
|
Young Adult | 8 | 2020 | 56392 | 0.180 |
Why?
|
Perivascular Epithelioid Cell Neoplasms | 1 | 2020 | 75 | 0.170 |
Why?
|
Pathology, Surgical | 1 | 2020 | 155 | 0.170 |
Why?
|
Cell Nucleus | 3 | 2020 | 2969 | 0.170 |
Why?
|
Myofibroblasts | 1 | 2021 | 222 | 0.170 |
Why?
|
Alphapapillomavirus | 1 | 2022 | 221 | 0.160 |
Why?
|
Lymphatic Metastasis | 4 | 2022 | 2924 | 0.160 |
Why?
|
Retinoblastoma Binding Proteins | 1 | 2019 | 98 | 0.160 |
Why?
|
Chemotherapy, Adjuvant | 6 | 2023 | 3480 | 0.160 |
Why?
|
Fibroadenoma | 1 | 2018 | 43 | 0.160 |
Why?
|
Cicatrix | 1 | 2024 | 763 | 0.160 |
Why?
|
Phyllodes Tumor | 1 | 2018 | 53 | 0.150 |
Why?
|
Neoplasms, Cystic, Mucinous, and Serous | 1 | 2020 | 198 | 0.150 |
Why?
|
Tumor Burden | 3 | 2021 | 1917 | 0.150 |
Why?
|
Nucleic Acid Hybridization | 1 | 2019 | 1374 | 0.150 |
Why?
|
Societies, Medical | 4 | 2023 | 3740 | 0.150 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p18 | 1 | 2017 | 53 | 0.150 |
Why?
|
PTEN Phosphohydrolase | 1 | 2023 | 1142 | 0.150 |
Why?
|
Colorectal Neoplasms | 2 | 2019 | 6773 | 0.150 |
Why?
|
Conization | 1 | 2016 | 14 | 0.150 |
Why?
|
Neprilysin | 2 | 2018 | 439 | 0.140 |
Why?
|
Chromogranins | 1 | 2017 | 163 | 0.140 |
Why?
|
Electrosurgery | 1 | 2016 | 58 | 0.140 |
Why?
|
Keratin-20 | 1 | 2016 | 31 | 0.140 |
Why?
|
Physicians, Women | 1 | 2022 | 486 | 0.140 |
Why?
|
Mucin-2 | 1 | 2016 | 49 | 0.140 |
Why?
|
Disease Progression | 4 | 2019 | 13273 | 0.140 |
Why?
|
Mitotic Index | 1 | 2016 | 172 | 0.140 |
Why?
|
Ribonuclease III | 1 | 2017 | 275 | 0.130 |
Why?
|
GTP-Binding Protein alpha Subunits, Gs | 1 | 2017 | 202 | 0.130 |
Why?
|
Ontario | 1 | 2016 | 383 | 0.130 |
Why?
|
Mastectomy, Segmental | 1 | 2020 | 956 | 0.130 |
Why?
|
Risk Assessment | 6 | 2023 | 23327 | 0.130 |
Why?
|
Reference Standards | 1 | 2019 | 1023 | 0.130 |
Why?
|
Radiotherapy, Adjuvant | 4 | 2023 | 1770 | 0.130 |
Why?
|
Proportional Hazards Models | 3 | 2019 | 12354 | 0.130 |
Why?
|
Proto-Oncogene Proteins c-mdm2 | 1 | 2017 | 381 | 0.130 |
Why?
|
Cesarean Section | 1 | 2024 | 1365 | 0.130 |
Why?
|
Treatment Outcome | 6 | 2021 | 63042 | 0.130 |
Why?
|
Carcinoma, Neuroendocrine | 1 | 2019 | 332 | 0.130 |
Why?
|
DEAD-box RNA Helicases | 1 | 2017 | 375 | 0.120 |
Why?
|
Neoplasms | 2 | 2020 | 21675 | 0.120 |
Why?
|
Immediate-Early Proteins | 1 | 2017 | 453 | 0.120 |
Why?
|
Physicians | 2 | 2023 | 4569 | 0.120 |
Why?
|
Kaplan-Meier Estimate | 3 | 2021 | 6539 | 0.120 |
Why?
|
Monitoring, Intraoperative | 1 | 2021 | 957 | 0.120 |
Why?
|
Cyclin-Dependent Kinase 4 | 1 | 2017 | 539 | 0.120 |
Why?
|
International Cooperation | 1 | 2020 | 1419 | 0.120 |
Why?
|
DNA, Viral | 1 | 2020 | 2226 | 0.120 |
Why?
|
Cyclin-Dependent Kinase Inhibitor p16 | 1 | 2017 | 705 | 0.120 |
Why?
|
RNA, Viral | 1 | 2022 | 2901 | 0.110 |
Why?
|
Cell Shape | 1 | 2014 | 375 | 0.110 |
Why?
|
Human papillomavirus 11 | 1 | 2013 | 14 | 0.110 |
Why?
|
Human papillomavirus 6 | 1 | 2013 | 16 | 0.110 |
Why?
|
Progesterone Congeners | 1 | 2013 | 42 | 0.110 |
Why?
|
Neoplasms, Squamous Cell | 1 | 2013 | 96 | 0.110 |
Why?
|
Gene Dosage | 1 | 2017 | 1252 | 0.110 |
Why?
|
Carcinoma, Renal Cell | 2 | 2022 | 3142 | 0.110 |
Why?
|
Molecular Diagnostic Techniques | 1 | 2017 | 602 | 0.110 |
Why?
|
Cell Size | 1 | 2014 | 641 | 0.110 |
Why?
|
Sequence Analysis, RNA | 1 | 2021 | 2009 | 0.110 |
Why?
|
Uterine Cervical Diseases | 1 | 2013 | 77 | 0.110 |
Why?
|
Adenoma | 1 | 2023 | 2173 | 0.110 |
Why?
|
Guidelines as Topic | 1 | 2019 | 1404 | 0.100 |
Why?
|
Metaplasia | 1 | 2013 | 313 | 0.100 |
Why?
|
In Situ Hybridization | 1 | 2016 | 1952 | 0.100 |
Why?
|
Reproducibility of Results | 4 | 2021 | 19894 | 0.100 |
Why?
|
Lymphocytosis | 1 | 2012 | 119 | 0.100 |
Why?
|
Hemorrhage | 1 | 2023 | 3458 | 0.100 |
Why?
|
Mesenteric Artery, Superior | 1 | 2011 | 101 | 0.100 |
Why?
|
Stomach Neoplasms | 1 | 2021 | 1332 | 0.100 |
Why?
|
Neoadjuvant Therapy | 2 | 2020 | 2727 | 0.100 |
Why?
|
Kidney Neoplasms | 2 | 2022 | 4260 | 0.100 |
Why?
|
Hemangioendothelioma | 1 | 2011 | 121 | 0.100 |
Why?
|
High-Throughput Nucleotide Sequencing | 2 | 2023 | 3591 | 0.090 |
Why?
|
Mitosis | 1 | 2016 | 1207 | 0.090 |
Why?
|
Microfilament Proteins | 1 | 2016 | 1152 | 0.090 |
Why?
|
Treatment Failure | 1 | 2016 | 2617 | 0.090 |
Why?
|
Hemangiosarcoma | 1 | 2012 | 239 | 0.090 |
Why?
|
Cystadenoma, Serous | 1 | 2010 | 102 | 0.090 |
Why?
|
Vaccination | 1 | 2022 | 3275 | 0.090 |
Why?
|
Nephrectomy | 2 | 2012 | 1048 | 0.090 |
Why?
|
Uterine Cervical Dysplasia | 1 | 2013 | 387 | 0.090 |
Why?
|
Ubiquitin-Protein Ligases | 1 | 2019 | 1861 | 0.090 |
Why?
|
Phenotype | 3 | 2017 | 16361 | 0.090 |
Why?
|
Education, Medical, Graduate | 1 | 2022 | 2291 | 0.090 |
Why?
|
Case-Control Studies | 2 | 2017 | 21733 | 0.090 |
Why?
|
Sequence Analysis, DNA | 1 | 2020 | 4803 | 0.080 |
Why?
|
Portal Vein | 1 | 2011 | 437 | 0.080 |
Why?
|
DNA Copy Number Variations | 1 | 2017 | 1937 | 0.080 |
Why?
|
Time Factors | 3 | 2017 | 40038 | 0.080 |
Why?
|
Terminology as Topic | 1 | 2016 | 1546 | 0.080 |
Why?
|
Premenopause | 1 | 2013 | 1033 | 0.080 |
Why?
|
Neoplasms, Multiple Primary | 1 | 2012 | 604 | 0.080 |
Why?
|
Kidney Glomerulus | 1 | 2011 | 697 | 0.080 |
Why?
|
Fatal Outcome | 1 | 2013 | 1851 | 0.080 |
Why?
|
Intestinal Perforation | 1 | 2010 | 253 | 0.080 |
Why?
|
Peritonitis | 1 | 2010 | 365 | 0.080 |
Why?
|
Public Health | 1 | 2020 | 2603 | 0.080 |
Why?
|
Image Interpretation, Computer-Assisted | 1 | 2020 | 3320 | 0.070 |
Why?
|
Genital Neoplasms, Female | 1 | 2012 | 523 | 0.070 |
Why?
|
Receptor Protein-Tyrosine Kinases | 1 | 2015 | 1660 | 0.070 |
Why?
|
Epithelial Cells | 2 | 2020 | 3690 | 0.070 |
Why?
|
Genetic Predisposition to Disease | 2 | 2019 | 17439 | 0.070 |
Why?
|
DNA | 1 | 2020 | 7295 | 0.070 |
Why?
|
Kidney | 2 | 2012 | 7185 | 0.070 |
Why?
|
Clinical Competence | 1 | 2022 | 4687 | 0.070 |
Why?
|
Survival Rate | 3 | 2021 | 12786 | 0.070 |
Why?
|
Pancreatectomy | 1 | 2010 | 804 | 0.070 |
Why?
|
Vagina | 2 | 2022 | 825 | 0.070 |
Why?
|
Cell Transformation, Neoplastic | 1 | 2015 | 2942 | 0.060 |
Why?
|
Biomedical Research | 1 | 2020 | 3308 | 0.060 |
Why?
|
Databases, Factual | 1 | 2019 | 7729 | 0.060 |
Why?
|
Gene Expression Profiling | 2 | 2017 | 9440 | 0.060 |
Why?
|
Risk | 1 | 2016 | 9677 | 0.060 |
Why?
|
Cell Proliferation | 2 | 2017 | 10477 | 0.060 |
Why?
|
Central Nervous System Neoplasms | 1 | 2012 | 895 | 0.060 |
Why?
|
Skin Neoplasms | 1 | 2023 | 5691 | 0.060 |
Why?
|
Adolescent | 3 | 2023 | 85729 | 0.060 |
Why?
|
Lymphoma | 1 | 2012 | 1875 | 0.060 |
Why?
|
Pancreatic Neoplasms | 2 | 2011 | 5264 | 0.060 |
Why?
|
Fumarate Hydratase | 1 | 2022 | 47 | 0.050 |
Why?
|
DNA-Binding Proteins | 1 | 2019 | 9648 | 0.050 |
Why?
|
Rupture | 1 | 2023 | 433 | 0.050 |
Why?
|
Groin | 1 | 2021 | 105 | 0.050 |
Why?
|
Gestational Age | 1 | 2010 | 3488 | 0.050 |
Why?
|
Follow-Up Studies | 2 | 2021 | 39001 | 0.050 |
Why?
|
Cohort Studies | 5 | 2022 | 40545 | 0.050 |
Why?
|
Proteins | 1 | 2016 | 6098 | 0.050 |
Why?
|
Infant, Premature | 1 | 2010 | 2031 | 0.050 |
Why?
|
Combined Modality Therapy | 2 | 2023 | 8637 | 0.050 |
Why?
|
Injections, Intraperitoneal | 1 | 2020 | 424 | 0.040 |
Why?
|
Atherosclerosis | 2 | 2012 | 3445 | 0.040 |
Why?
|
Male | 8 | 2023 | 349776 | 0.040 |
Why?
|
Diagnostic Self Evaluation | 1 | 2021 | 230 | 0.040 |
Why?
|
Fertility | 1 | 2023 | 779 | 0.040 |
Why?
|
Preoperative Period | 1 | 2020 | 550 | 0.040 |
Why?
|
Cysteine | 1 | 2022 | 871 | 0.040 |
Why?
|
Feedback | 1 | 2022 | 795 | 0.040 |
Why?
|
DNA Helicases | 1 | 2023 | 861 | 0.040 |
Why?
|
Vaginal Smears | 1 | 2020 | 511 | 0.040 |
Why?
|
Multiple Sclerosis | 1 | 2012 | 3079 | 0.040 |
Why?
|
North America | 1 | 2021 | 1249 | 0.040 |
Why?
|
Education, Distance | 1 | 2021 | 251 | 0.040 |
Why?
|
Antineoplastic Agents | 1 | 2020 | 13691 | 0.040 |
Why?
|
United States | 3 | 2023 | 69859 | 0.040 |
Why?
|
Risk Factors | 3 | 2019 | 72252 | 0.040 |
Why?
|
Neoplastic Syndromes, Hereditary | 1 | 2019 | 241 | 0.040 |
Why?
|
Child | 1 | 2024 | 77637 | 0.030 |
Why?
|
Sepsis | 1 | 2010 | 2593 | 0.030 |
Why?
|
Lymphatic Vessels | 1 | 2019 | 353 | 0.030 |
Why?
|
Digestive System Surgical Procedures | 1 | 2020 | 576 | 0.030 |
Why?
|
Europe | 1 | 2021 | 3336 | 0.030 |
Why?
|
Oncogenes | 1 | 2019 | 1265 | 0.030 |
Why?
|
Tissue Array Analysis | 1 | 2015 | 553 | 0.030 |
Why?
|
Blood Vessels | 1 | 2019 | 1124 | 0.030 |
Why?
|
Inflammation | 1 | 2012 | 10629 | 0.030 |
Why?
|
Drug Administration Schedule | 1 | 2020 | 4931 | 0.030 |
Why?
|
Paracentesis | 1 | 2012 | 95 | 0.030 |
Why?
|
ROC Curve | 1 | 2018 | 3527 | 0.020 |
Why?
|
Ascites | 1 | 2012 | 344 | 0.020 |
Why?
|
Infant, Newborn | 1 | 2010 | 25609 | 0.020 |
Why?
|
Magnetic Resonance Imaging | 2 | 2013 | 35409 | 0.020 |
Why?
|
Sex Factors | 1 | 2022 | 10394 | 0.020 |
Why?
|
Prospective Studies | 2 | 2023 | 53250 | 0.020 |
Why?
|
Nuclear Proteins | 1 | 2023 | 5854 | 0.020 |
Why?
|
Constriction, Pathologic | 1 | 2011 | 1108 | 0.020 |
Why?
|
Hypolipidemic Agents | 1 | 2012 | 606 | 0.020 |
Why?
|
Mammography | 1 | 2019 | 2475 | 0.020 |
Why?
|
Transfection | 1 | 2015 | 5892 | 0.020 |
Why?
|
Chi-Square Distribution | 1 | 2013 | 3503 | 0.020 |
Why?
|
Research Design | 1 | 2022 | 5983 | 0.020 |
Why?
|
Oligonucleotide Array Sequence Analysis | 1 | 2015 | 3917 | 0.020 |
Why?
|
Pilot Projects | 1 | 2019 | 8316 | 0.020 |
Why?
|
RNA Interference | 1 | 2015 | 2890 | 0.020 |
Why?
|
Heterozygote | 1 | 2012 | 2803 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2012 | 1064 | 0.020 |
Why?
|
Creatinine | 1 | 2011 | 1918 | 0.020 |
Why?
|
Diabetes Complications | 1 | 2012 | 1360 | 0.020 |
Why?
|
Multivariate Analysis | 1 | 2018 | 12243 | 0.020 |
Why?
|
Fibrosis | 1 | 2011 | 2030 | 0.020 |
Why?
|
Postmenopause | 1 | 2012 | 2458 | 0.010 |
Why?
|
Cross-Sectional Studies | 1 | 2023 | 25032 | 0.010 |
Why?
|
Gene Expression Regulation, Neoplastic | 1 | 2015 | 8430 | 0.010 |
Why?
|
Cell Line, Tumor | 1 | 2015 | 16674 | 0.010 |
Why?
|
Comorbidity | 1 | 2012 | 10380 | 0.010 |
Why?
|
Brain Neoplasms | 1 | 2019 | 8856 | 0.010 |
Why?
|
Genome-Wide Association Study | 1 | 2015 | 12259 | 0.010 |
Why?
|
Prevalence | 1 | 2012 | 15211 | 0.010 |
Why?
|
Severity of Illness Index | 1 | 2012 | 15526 | 0.010 |
Why?
|
Incidence | 1 | 2011 | 20948 | 0.010 |
Why?
|
Coronary Artery Disease | 1 | 2012 | 6485 | 0.010 |
Why?
|
Hypertension | 1 | 2012 | 8480 | 0.010 |
Why?
|
Signal Transduction | 1 | 2015 | 23398 | 0.010 |
Why?
|
Infant | 1 | 2011 | 35122 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2011 | 20121 | 0.010 |
Why?
|